- John Hanna appointed
Interim CFO to replace departing CFO Tim Hendrickson
TORONTO, Dec. 18, 2023 /CNW/ - HLS Therapeutics Inc.
("HLS" or the "Company") (TSX: HLS), a pharmaceutical company
focused on addressing unmet needs in the treatment of psychiatric
disorders and cardiovascular disease, announces that Tim Hendrickson is stepping down as CFO to
pursue other interests and John
Hanna, currently a director of the Company, has been
appointed Interim CFO. Mr. Hendrickson will remain in his role
until January 26, 2024, to support
the transition and the Company will undertake a search for a
permanent CFO in the new year.
"As one of the Company's first hires, Tim played an important
role in helping HLS build its portfolio, achieve its public listing
and manage its ongoing operations," said Craig Millian, CEO of HLS. "On behalf of the
team and the Board, I'd like to thank him for his contributions and
commitment, and I wish him the best in his future pursuits."
Mr. Millian continued: "John's background as a public company
CFO along with his experience on our Board and his role on the
Audit Committee make him a great fit as Interim CFO. I look forward
to working more closely with John as we seek to drive top-line
growth and margin expansion with the marketed products in our
portfolio."
While serving as Interim CFO, Mr. Hanna will remain on the HLS
Board as a non-independent director.
Mr. Hanna is an accomplished leader with more than 25 years of
diverse experience, including in the healthcare industry, as a
C-level executive helping companies to drive revenue growth, scale
their operations and expand operating profitability. Previously, he
served as CFO at Vecima Networks (TSX:VCM), Inca Networks and
eBuyNow and held a variety of senior financial roles with The
Westaim Corporation. In addition to being a member of HLS's Board
and the Audit Committee, Mr. Hanna has also served as a board
member for a number of technology companies. He holds a B.Sc.,
Biology from University of Victoria, an
MBA from the University of British
Columbia and is a designated accountant (CPA, CGA).
ABOUT HLS THERAPEUTICS
INC.
Formed in 2015, HLS is a pharmaceutical company focused on the
acquisition and commercialization of late-stage development,
commercial stage promoted and established branded pharmaceutical
products in the North American markets. HLS's focus is on products
targeting unmet needs in the treatment of psychiatric disorders and
cardiovascular disease. HLS's management team is composed of
seasoned pharmaceutical executives with a strong track record of
success in these therapeutic areas and at managing products in each
of these lifecycle stages. For more information visit:
www.hlstherapeutics.com
FORWARD LOOKING
INFORMATION
This release includes forward-looking statements regarding
HLS and its business. Such statements are based on the current
expectations and views of future events of HLS's management. In
some cases the forward-looking statements can be identified by
words or phrases such as "may", "will", "expect", "plan",
"anticipate", "intend", "potential", "estimate", "believe" or the
negative of these terms, or other similar expressions intended to
identify forward-looking statements, including, among others,
statements with respect to HLS's pursuit of additional product and
pipeline opportunities in certain therapeutic markets, statements
regarding growth opportunities, and expectations regarding
financial performance. The forward-looking events and circumstances
discussed in this release may not occur and could differ materially
as a result of known and unknown risk factors and uncertainties
affecting HLS, including risks relating to the specialty
pharmaceutical industry, risks related to the regulatory approval
process, economic factors and many other factors beyond the control
of HLS. Forward-looking statements and information by their nature
are based on assumptions and involve known and unknown risks,
uncertainties and other factors which may cause HLS's actual
results, performance or achievements, or industry results, to be
materially different from any future results, performance or
achievements expressed or implied by such forward-looking statement
or information. Accordingly, readers should not place undue
reliance on any forward-looking statements or information. A
discussion of the material risks and assumptions associated with
this release can be found in the Company's Annual Information Form
dated March 15, 2023, and
Management's Discussion and Analysis dated November 8, 2023, both of which have been filed
on SEDAR and can be accessed at www.sedarplus.ca. Accordingly,
readers should not place undue reliance on any forward-looking
statements or information. Except as required by applicable
securities laws, forward-looking statements speak only as of the
date on which they are made and HLS undertakes no obligation to
publicly update or revise any forward-looking statement, whether as
a result of new information, future events, or otherwise.
SOURCE HLS Therapeutics Inc.